Dr. Jonathan Brotchie
Senior Scientist, Toronto Western Research Institute, University Health Network
Senior Scientist, Toronto Western Research Institute, University Health Network (2002-present). He gained his PhD, in Neuroscience, from the University of Manchester, UK, for research on the role of the subthalamic nucleus in the generation of symptoms of Parkinson’s disease (PD) (1991). He has more than 25 years’ experience in Parkinson’s disease research, managing teams in both academia and in commercial environments that have identified and validated several drug targets for PD. He has lead translational research that has supported the assessment of efficacy of 48 drug candidates in non-human primate models of PD and the advancement of 14 drug candidates to clinical studies. Dr Brotchie has also been named inventor/ co-inventor on 13 families of patents related to novel therapeutics for movement disorders. Dr Brotchie has published more than 140 peer-reviewed academic papers, he has consulted for more than 45 biopharmaceutical companies as well as for members for the financial community and works closely with, as an advisor to, several Parkinson’s disease charities. In the commercial realm, he has founded, and held senior management positions in, two successful companies providing Parkinson’s disease-focused, drug development services to the pharmaceutical industry, Atuka Inc (2003-present) and Motac Ltd (1999-2002). More recently, he is a co-Founder and President of Junaxo Inc (2013-present), a drug development company with a focus on neurodegenerative diseases, particularly PD and ALS.